Free Nephrology CME

Using a quiz-based format, this accredited CME activity offers a brief, interactive microlearning experience centered around a clinical case scenario, enabling clinicians to quickly test their understanding of weight-related eligibility criteria for kidney transplantation, compare their answers with peer responses, and gain expert insights through video commentary. Faculty explore how obesity affects transplant candidacy, evaluation strategies, and potential interventions to optimize patients for transplant, as well as provide key takeaways to support informed, patient-centered clinical decisions.

In this online, self-learning activity:

IgA nephropathy (IgAN) is an inflammatory kidney disease with IgA deposition in the glomerular mesangium. IgAN is the most prevalent primary chronic glomerular disease worldwide. Globally, IgAN has an estimated incidence of 25 cases per one million people annually. It is more common in children and young adults than in the elderly. Among patients of all ages, the average annual prevalence of IgAN in the United States is 329 per 1 million. The epidemiology and gender distribution of IgAN vary by country and region. In North America and Europe, the prevalence is higher in men.

Target Audience:

HCPs including: nephrologists, internists, and pediatricians; physician associates, nurse practitioners, and pharmacists who practice in those areas of specialty; and those who otherwise care for or clinically encounter patients with IgAN.

In this online, self-learning activity:

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), affecting over 40% of patients with lupus. It is a major contributor to morbidity, healthcare utilization, and progression to end-stage renal disease (ESRD). The prevalence of LN has increased significantly over time, from 16.8 per 100,000 in 1985 to 21.2 per 100,000 more recently. The mortality rate associated with LN remains high with a standardized mortality ratio of 6.33 compared to the general population. Despite increased advances in treatments, long-term survival rates have not improved significantly over the past four decades. The 10-year survival rate is around 70%, while the incidence of progression in ESRD in LN patients affects up to 13% of patients over time.